We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Genetic Determinants of the Response to Salbutamol Among Asthma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00162396
Recruitment Status : Unknown
Verified October 2008 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
First Posted : September 13, 2005
Last Update Posted : October 29, 2008
Information provided by:
Hadassah Medical Organization

September 11, 2005
September 13, 2005
October 29, 2008
August 1999
Not Provided
  • Change in lung function tests after salbutamol inhalation
  • Change in blood pressure and pulse after salbutamol inhalation
Same as current
Complete list of historical versions of study NCT00162396 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Genetic Determinants of the Response to Salbutamol Among Asthma Patients
Evaluation of Genetic Factors That May Account for Variability in the Response to Salbutamol Among Patients Suffering From Asthma

The response to salbutamol varies greatly among individuals. Data from previous studies indicate that some of the variability is accounted for by genetic polymorphisms in the gene encoding for the adrenoceptor subtype β2. The current study was designed to evaluate variability in the response to salbutamol among recently diagnosed patients who have not been treated by β2 agonists or corticosteroids.

Lung function tests will be performed prior to and following a single dose administration of salbutamol through inhalation. Additional pharmacodynamic indices will be monitored including pulse and blood pressure. Three samples of plasma will be drawn for the evaluation of salbutamol plasma concentration.

Not Provided
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Drug: Albuterol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided

Inclusion Criteria:

  • 18 years and older
  • Recently diagnosed as asthmatic

Exclusion Criteria:

  • Current treatment by β2 agonist
  • Current treatment by corticosteroids
  • Acute asthma attack
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: Yoseph Caraco, MD Hadassah Medical Organization
Hadassah Medical Organization
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP